press release

Novo Nordisk to present new semaglutide data on 'food noise', body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress

- The INFORM real-world evidence study shows impact of semaglutide on reducing 'food noise', and the STEP UP clinical trial highlights semaglutide's effect on control of eating and body composition after losing weight
- Next-generation obesity treatment cagrilintide demonstrates promise as standalone therapy (REDEFINE 1); data also being presented on amycretin
- The first head-to-head real-world study, REACH shows superiority of Ozempic® versus dulaglutide on cardiovascular events such as heart attack and stroke

Bagsværd, Denmark, 5 September 2025 – Novo Nordisk today announced the presentation of 35 abstracts from across its diabetes and obesity portfolio at the upcoming European Association for the Study of Diabetes (EASD) congress 2025 from 15 to 19 September in Vienna, Austria. The presentations include clinical and real-world data reinforcing semaglutide's broad health benefits, widest approved indications, and its well-established weight loss effect. Novo Nordisk will also present data on new obesity pipeline therapies, including CagriSema, cagrilintide and amycretin.

On 17 September, Novo Nordisk will also host an R&D investor event to cover the science and abstracts presented at the congress. The event will be accessible via a live webcast on the Novo Nordisk investor website.

"With the broadest approved indications in both obesity and type 2 diabetes, semaglutide is today making a real difference in helping people lose weight while also protecting them from cardiovascular events such as heart attacks," said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. "We are now leading the way in developing next-generation treatments – such as combining cagrilintide with semaglutide or using it as a monotherapy – to better meet the needs of people living with diabetes and obesity, and we are excited to present these data at EASD."

Novo Nordisk A/S
Global Communication

Novo Alle 1
2880 Bagsværd
Denmark

Tel: +45 4444 8888
www.novonordisk.com

CVR no: 24 25 67 90

Summary of presentations

Accepted data at the 61st annual meeting of the EASD include the following poster and oral presentations. Accepted abstracts include preliminary data that may be subject to change in the final published manuscripts. Dates and times of the presentations can be found on the EASD website.

EASD scientific symposia

- SOUL Trial: Effects of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk – Wednesday 17 September; 08:30 – 09:30 CEST

EASD poster and oral sessions

Wegovy® (once-weekly semaglutide 2.4 mg)

- Impact on food noise after initiating semaglutide treatment: results from a US survey (INFORM). **Short oral presentation (45-SO) - Tuesday 16 September; 12:00 – 13:00 CEST**
- Impact of once-weekly semaglutide on cardiovascular events in adults with overweight or obesity in a real-world Danish population. **Oral presentation (148-OR) - 18 September; 11:30 – 11:45 CEST**

Once-weekly semaglutide 7.2 mg

- Effect of semaglutide 7.2 mg on anthropometric measures of obesity: the STEP UP trial **Oral presentation (145-OR) - Thursday 18 September; 10:45 – 11:00 CEST**
- Control of eating with semaglutide 7.2 mg in adults with obesity: the STEP UP trial. **Oral presentation (146-OR) - Thursday 18 September; 11:00 – 11:15 CEST**
- Effect of semaglutide on body composition and proximal muscle strength: the STEP UP trial. **Oral presentation (147-OR) - Thursday 18 September: 11:15 – 11:20 CEST**

Ozempic® (once-weekly semaglutide 1.0 mg)

- Comparative effectiveness of once-weekly semaglutide vs dulaglutide on cardiovascular outcomes in US Medicare beneficiaries with type 2 diabetes and atherosclerotic cardiovascular disease. **Late breaking presentation (LBA-19) - Thursday 18 September; 10:45 – 11:00 CEST**

Rybelsus® (once-daily oral semaglutide)

- Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial. **Oral presentation (2-OR) - Tuesday 16 September; 10:15 – 10:30 CEST**

- Effects of oral semaglutide on hospitalisation rates in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL trial results. **Oral presentation (127-OR) - Wednesday 17 September; 14:30 – 14:45 CEST**

Semaglutide for MASH

- Impact of semaglutide on liver-related responses in people with metabolic dysfunction-associated steatohepatitis with/without type 2 diabetes: post hoc analysis of the ESSENCE trial. **Short oral presentation (555-SO) - Tuesday 16 September; 13:15 – 14:15 CEST**

CagriSema

- REDEFINE 2: a randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27kg/m2 and type 2 diabetes. **Oral presentation (73-OR) - Wednesday 17 September; 09:45 – 10:00 CEST**
- CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m2 and type 2 diabetes in the blinded continuous glucose monitoring subgroup in REDEFINE 2. **Oral presentation (13-OP) - Wednesday 17 September; 14:30 – 14:45 CEST**
- REDEFINE1: a randomised study of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of overweight or obesity in adults. **Oral presentation (190-OR) - Thursday 18 September; 16:15 – 16:30 CEST**

Cagrilintide

- Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: data from REDEFINE 1. **Short oral presentation (43-SO) - Tuesday 16 September; 12:00 – 13:00 CEST**

Amycretin

- Amycretin, a novel, unimolecular glucagon-like peptide-1 and amylin receptor agonist: results of a phase 1b/2a clinical trial. **Oral presentation (63-OR) - Tuesday 16 September; 15:15 – 15:30 CEST**
- Pharmacokinetics, safety and tolerability of amycretin in people with renal impairment. **Oral presentation (15-OR) - Wednesday 17 September; 15:00 – 15:15 CEST**
- The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. **Oral presentation (188-OR) - Thursday 18 September; 15:45 – 16:00 CEST**

About semaglutide
Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that mimics the effects of the naturally occurring hormone GLP-1, which regulates weight and blood sugar. It has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease, and other related cardiometabolic diseases[1-5]. Semaglutide has a well-established safety and tolerability profile supported by over 33 million patient-years of exposure since its launch in 2018[6].

Semaglutide is marketed under the brand names Wegovy® (once-weekly semaglutide 2.4 mg injection), Ozempic® (once-weekly semaglutide 1.0 mg injection), and Rybelsus® (once-daily oral semaglutide 14 mg).

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:

Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

Investors:

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Max Ung
+45 3077 6414
mxun@novonordisk.com

Christoffer Sho Togo Tullin
+45 3079 1471
cftu@novonordisk.com

Alex Bruce
+45 34 44 26 13
axeu@novonordisk.com

Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com

References

1. Perkovic V, Tuttle KR, Rossing P*, et al.* Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med*. 2024;391:109-121.
2. Marso SP, Bain SC, Consoli A*, et al.* Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375:1834-1844.
3. McGuire DK, Marx N, Mulvagh SL*, et al.* Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. *N Engl J Med*. 2025.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM*, et al.* Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023;389:2221-2232.
5. Pratley RE, Aroda VR, Lingvay I*, et al.* Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol*. 2018;6:275-286.
6. Novo Nordisk data on file (IQVIA MIDAS® monthly volume sales data for the time period Jan 2018 to July 2024 [40 countries]). Novo Nordisk A/S, Bagsværd, Denmark.

Novo Nordisk A/S
Global Communication

Novo Alle 1
2880 Bagsværd
Denmark

Tel: +45 4444 8888
www.novonordisk.com

CVR no: 24 25 67 90